Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onalespib with Cisplatin and Radiation in LA-SCCHN
NCT02381535Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2015
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of onalespib in squamous cell carcinoma of the head and neck (HNSCC), sponsored by National Cancer Institute. Primary endpoint: Maximum Tolerated Dose at 8 weeks. Started Oct 2015; status: completed.
02
Drugs
onalespib
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02381535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02381535.